The impact of age on psoriasis health care in Germany

Abstract

Middle-aged patients show higher rates of PsA and nail psoriasis, which may explain age-dependent disparities in health care including the use of systemic treatment.

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

“…Pronounced benefits in HRQoL were also observed in both populations. Upcoming real-world evidence from ongoing non-interventional studies and registries such as PROSPECT [ 22 ], SERENA or PsoBest [ 23 ] will be of interest to better characterize efficacy and safety of biologic treatments in elderly psoriasis patients. Further prospective studies are required to confirm the findings from this pooled analysis, which supports secukinumab as a treatment option for elderly subjects with psoriasis.…”

Elderly psoriatic patients under biological therapies: an Italian experience

“…reported a rapid PASI score reduction and maintenance in the long term in 27 elderly patients under treatment with infliximab. The German Psoriasis Registry PsoBest reported no differences in biologics prescription in patients aged 65 or over and patients aged 35–64 . Recently, Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis included also treatment recommendations for special psoriasis population, as elderly patients.…”

“…The German Psoriasis Registry PsoBest reported no differences in biologics prescription in patients aged 65 or over and patients aged 35-64. 13 Recently, Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis included also treatment recommendations for special psoriasis population, as elderly patients. The authors agreed that, for elderly patients requiring a systemic treatment, all therapy, including biologics, can be safely used, as long as they are appropriately screened and monitored.…”

Age-Dependent Indexes of Immunity in the Patients With Psoriatic Arthritis

“…Immune markers of psoriatic arthritis 2019, Vol. 21 При сравнении основных иммунологических показателей клеточного звена иммунитета и цитокинового профиля в группах больных ПсА в зрелом возрасте относительно контроля не выявлено статистически значимых различий относительного и абсолютного количества CD3 + CD4 + , CD3 -CD19 + лимфоцитов, концентрации TNFα.…”

“…Однако в литературе описаны примеры повышения концентрации цитокинов Th2-профиля в сыворотке крови при тяжелых формах заболевания, таких как псориатическая эритродермия и пустулезный генерализованный псориаз [23]. Отмечено, что псориатический процесс имеет особенности клинического течения в зависимости от возраста [21]. Значительный интерес представляет изучение показателей иммунореактивности при ПсА в различных возрастных группах, что позволит выявить особенности прогрессирования патологии.…”